In a phase 2 trial, a vaccine (Ad.p53-DC) containing dendritic cells transfected with wild-type TP53 failed to improve the response to chemotherapy in recurrent ES-SCLC patients, but its safety and therapeutic immune potential remain encouraging [265]. This evidence concerns the gene TP53 and small cell lung carcinoma.